Connect with us

Business

Antibody Treatments, Though Promising, Will Be in Short Supply – The New York Times

All the weak points of American health care — testing delays, communication breakdowns, inequity — are working against this potential treatment.

Published

on

post featured image
ADVERTISEMENT

If the antibody treatments prove effective, they are expected to become more widely available by early next year. Regeneron has said it will be able to produce about 250,000 doses a month in partnership with Roche. Eli Lilly has said it will also be able to ramp up production. Another company, AstraZeneca, is also developing an antibody treatment that is earlier in its development, and it has a deal with the federal government to supply up to 100,000 doses by the end of December.
In the meantim…

Click here to view the original article.

Continue Reading
Advertisement

You might also like ...

post featured image
Kelby Krabbenhoft out as Sanford Health CEO, after email about COVID-19, masks – INFORUM
post featured image
Dow futures rise 100 points after record day on Wall Street – CNBC
post featured image
Best Black Friday Vacuum Deals from Dyson, Roomba, and Shark – The New York Times